

550,608

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number  
**WO 2004/085676 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68,**  
G01N 33/574

(21) International Application Number:  
PCT/EP2004/003219

(22) International Filing Date: 25 March 2004 (25.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P200300708 26 March 2003 (26.03.2003) ES

(71) Applicant (for all designated States except US): **MED-PLANT GENETICS, S.L.** [ES/ES]; Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MARTINEZ MARTINEZ, Antonio** [ES/ES]; Medplant Genitrics, S.L., Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES). **SIMÓN BUELA, Laureano** [ES/ES]; Medplant Genetics, S.L., Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES). **SANTA CRUZ, Simón** [ES/ES]; Medplant Genetics, S.L., Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES). **SÁENZ JIMÉNEZ, María Pilar** [ES/ES]; Medplant Genetics, S.L., Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES). **MOLINA VILA, Miguel** [ES/ES]; Medplant Genetics, S.L., Edificio 801A. Parque Tecnológico de Zamudio, E-48160 Derio (ES). **JUNQUERA SÁNCHEZ-VALLEJO, Corina** [ES/ES]; Medplant Genetics, S.L., Edificio 801A. Parque Tecnológico de

Zamudio, E-48160 Derio (ES). **GÓMEZ ROMÁN, José Javier** [ES/ES]; Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla, E-39008 Santander (ES). **CUEVAS GONZÁLEZ, JORGE** [ES/ES]; Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla, E-39008 Santander (ES).

(74) Agent: **PORTELA, Sergio**; ABG Patentes, S.L., Orense, 16 8°A, E-28020 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA

(57) Abstract: The present invention refers to an *in vitro* method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.

WO 2004/085676 A1